Compounded vs Branded GLP-1: What You Actually Need to Know in 2026

If you've been researching weight-loss medications, you've probably hit the term "compounded GLP-1" and wondered what it means, whether it's safe, and whether it's actually different from the brand-name versions. Short answer: it's complicated, and what was true in 2023 is no longer true in 2026.

This article walks through the actual difference between compounded and branded GLP-1s, the FDA shortage that made compounded versions possible, what changed in 2025, and how to think about the two options now.

The two big drugs, explained quickly

Two molecules dominate the GLP-1 conversation:

• Semaglutide — sold as Wegovy (for chronic weight management) and Ozempic (for type-2 diabetes). Same molecule, different doses and FDA labels.
• Tirzepatide — technically a dual GIP/GLP-1 agonist, but lumped into the GLP-1 conversation. Sold as Zepbound (weight) and Mounjaro (diabetes). Same molecule, different labels.

Both are made by big pharma — Novo Nordisk owns semaglutide, Eli Lilly owns tirzepatide. Both are protected by patents that don't expire for several years.

So how were so many telehealth platforms selling "semaglutide" for $200/month in 2023 if it's still under patent and Wegovy retails for $1,300/month?

The FDA shortage loophole (2022–2024)

Here's the thing most people miss: the FDA maintains an official drug shortage list. When a medication is on it, U.S. compounding pharmacies are legally allowed to produce a copy of that drug. This is called 503A compounding (patient-specific) or 503B outsourcing (bulk).

In 2022, demand for semaglutide and tirzepatide outpaced manufacturing capacity. The FDA added both to the shortage list. Suddenly, hundreds of compounding pharmacies could legally produce versions of these drugs and sell them at a fraction of the brand-name price.

This is what powered the entire DTC weight-loss telehealth boom. Hims, Henry Meds, Mochi Health, dozens of others built businesses on $200–$300/month compounded semaglutide subscriptions while brand-name Wegovy was $1,300+/month.

What changed in 2025

In late 2024 and through 2025, both Novo Nordisk and Eli Lilly ramped up manufacturing dramatically. The FDA officially declared the semaglutide shortage resolved in early 2025, and the tirzepatide shortage followed shortly after.

Once a shortage ends, the legal basis for mass-compounding disappears. Compounding pharmacies that continued to mass-produce these drugs faced cease-and-desist letters, FDA warning letters, and in some cases, civil action from Novo and Lilly.

Where things stand now:

• Mass compounding of semaglutide and tirzepatide is no longer broadly legal in the way it was in 2023.
• Patient-specific compounding under section 503A is still legal for documented medical need (e.g. allergic reactions to brand-name fillers, specific dosing requirements). This is a much narrower lane.
• Some telehealth platforms continued operating in this narrower lane — Henry Meds is one. Others pivoted to branded medications. Many shut down.
• The cheapest "$99 compounded GLP-1" offers from 2023 are mostly gone, or are operating in a legally murky space.

So which should you choose?

Here's the honest version of the trade-offs:

Branded (Wegovy, Zepbound, Ozempic, Mounjaro)

Pros:

• FDA-approved, with extensive clinical trial data behind the specific finished product.
• Manufacturing is tightly controlled — every batch tested.
• Insurance is more likely to cover it (especially for diabetes; weight is harder).
• Pen injectors come pre-filled and ready.

Cons:

• Cash price is $1,000–$1,400/month without insurance.
• Insurance approval can be difficult for weight-loss-only indications.
• Supply, while better, is not infinite.

Compounded (legal patient-specific 503A)

Pros:

• Lower cash cost — typically $200–$400/month.
• Available without insurance gymnastics.
• Some compounded options come in vials with syringes, allowing dose flexibility.

Cons:

• Less manufacturing oversight — quality varies by pharmacy.
• The legal basis for compounding has narrowed significantly. If your provider is operating outside the 503A patient-specific lane, you're in murky territory.
• No formal clinical trial data on the specific compounded preparation.
• Side-effect profile may differ slightly depending on excipients (fillers).

What we'd actually recommend in 2026

Three honest takes:

1. If insurance covers branded for you, take that path. Better data, no legal ambiguity, no risk of your supply disappearing if regulations tighten further.

2. If insurance doesn't cover it and brand-name cash price is a non-starter, look for telehealth providers operating clearly within the 503A patient-specific compounding lane (Henry Meds, Mochi). Avoid platforms making vague claims about "FDA-approved compounded GLP-1" — that phrase is a regulatory red flag.

3. Avoid anything labeled "research peptide," "GLP-1 alternative," or sold without a clinician review. These are the platforms most likely to be selling unregulated material with unknown contents.

Side effects don't differ meaningfully by source

A common myth: "compounded is more side-effect-heavy than branded." There's no good evidence this is broadly true. Side effects of GLP-1 medications come primarily from the molecule itself, not the source. Both branded and well-made compounded versions cause similar nausea, constipation, fatigue, and the rare more serious effects.

The variable is manufacturing quality, not branded vs compounded as a category. A reputable 503A pharmacy producing patient-specific semaglutide is going to be safer than a fly-by-night operation regardless of what label is on the vial.

The bottom line

The 2023 era of cheap, easy compounded GLP-1s is over. What replaced it is messier: branded medications at premium prices, narrower compounding lanes for specific patients, and a lot of marketing noise from platforms that haven't fully adjusted to the new rules.

Pick a provider that's transparent about how their medication is sourced. Ask whether it's branded or compounded. If compounded, ask under what regulatory basis. Don't accept hand-waving answers. The good platforms will explain it clearly; the iffy ones will deflect.

If you want help comparing the platforms operating in this new landscape, see our roundup of the best GLP-1 telehealth programs.

---

This article includes affiliate links. We may earn a commission when you sign up through links on this page, at no additional cost to you. Editorial coverage and rankings are not influenced by these relationships. We are not a healthcare provider — final decisions about medications belong to you and a licensed clinician.